A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Navigating these stocks isn’t easy, which is why StockStory helps you find Comfort In Chaos. That said, here are two volatile stocks that could deliver huge gains and one that might not be worth the risk.
One Stock to Sell:
NN (NNBR)
Rolling One-Year Beta: 2.09
Formerly known as Nuturn, NN (NASDAQ:NNBR) provides metal components, bearings, and plastic and rubber components to the automotive, aerospace, medical, and industrial sectors.
Why Are We Out on NNBR?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 1.3% annually over the last five years
- Sales were less profitable over the last five years as its earnings per share fell by 16.9% annually, worse than its revenue declines
- Long-term business health is up for debate as its cash burn has increased over the last five years
NN is trading at $1.95 per share, or 292x forward P/E. Dive into our free research report to see why there are better opportunities than NNBR.
Two Stocks to Watch:
SPX Technologies (SPXC)
Rolling One-Year Beta: 1.58
SPX Technologies (NYSE:SPXC) is an industrial conglomerate catering to the energy, manufacturing, automotive, and aerospace sectors.
Why Could SPXC Be a Winner?
- Impressive 13.5% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Operating profits and efficiency rose over the last five years as it benefited from some fixed cost leverage
- Earnings per share have massively outperformed its peers over the last two years, increasing by 25.5% annually
SPX Technologies’s stock price of $166.50 implies a valuation ratio of 26.2x forward P/E. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.
Hims & Hers Health (HIMS)
Rolling One-Year Beta: 3.24
Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.
Why Will HIMS Outperform?
- Customer trends over the past two years show it’s maintaining a steady flow of new contracts that can potentially increase in value over time
- Earnings growth has massively outpaced its peers over the last four years as its EPS has compounded at 37% annually
- Free cash flow margin expanded by 23.5 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
At $46.30 per share, Hims & Hers Health trades at 35x forward EV-to-EBITDA. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today